Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor. The study (IAVI C105/PREVAIL15) is funded by CEPI, an innovative global partnership working to accelerate the development of vaccines against epidemic and pandemic threats.
LTC Natalie Collins, Director of EIDB at WRAIR, and Dr. Gordon Joyce are presenting at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Silver Spring, Md. - In collaboration with the African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) and HJFMRI, Walter Reed Army Institute of Research (WRAIR) completed a study demonstrating, for the first time, that non-rodents such as lizards, pigs, dogs, sheep, goats and cattle are reservoirs for Lassa virus (LASV) in southern Nigeria.
Two laboratories at military facilities supported by the Walter Reed Program-Nigeria (WRP-N) were granted ISO15189 accreditation by the Medical Laboratory Science Council of Nigeria. The two newly accredited laboratories are the 68 Nigerian Army Reference Hospital Laboratory, Yaba (NARHY), Lagos and the 063 Nigerian Air Force Hospital Laboratory (063NAFH).
Scientists with the Walter Reed Army Institute of Research (WRAIR) have found that immunizing nurse sharks with experimental SARS-CoV-2 vaccines elicited a set of unique nano-sized antibodies that broadly neutralize a range of viruses in the SARS-CoV family and confer passive immune protection in a mouse virus challenge model. Findings were published in Nature Communications.
